New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

17 Jun 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Nature Reviews Clinical Oncology, Published online: 17 June 2026; doi:10.1038/s41571-026-01168-5 The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy.
Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose.

Clinical Editorial

Nature Reviews Clinical Oncology published a clinical update in Oncology on 17 Jun 2026. The item focuses on New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

Br J CancerRelated by Drugpembrolizumab

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Oncology • 18 Apr 2026

ClinicalTrialsRelated by Drugpembrolizumab

Surgical Pembro +/- Olaparib w TMZ for rGBM

Oncology • 04 Mar 2026

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

Infectious Disease • 13 Jul 2026

JCORelated by Drugpembrolizumab

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

Oncology • 14 Apr 2026

ESMO OpenRelated by Drugpembrolizumab

Durvalumab Plus Weekly Carboplatin and Paclitaxel in Cisplatin-Ineligible Recurrent or Metastati

Oncology • 09 Apr 2026

JAMA OncRelated by Drugpembrolizumab

Outcomes and Treatments After Pembrolizumab in Non–Small Cell Lung Cancer

Oncology • 09 Apr 2026

Feed Metadata

Source

Nature Reviews Clinical Oncology

New standards and new&#xa0;constraints redefine treatment sequencing in platinum-resistant ovarian cancer

GIST (Key Takeaways)

Clinical Editorial

Source Reference

Related by Condition/Drug

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Surgical Pembro +/- Olaparib w TMZ for rGBM

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

Durvalumab Plus Weekly Carboplatin and Paclitaxel in Cisplatin-Ineligible Recurrent or Metastati

Outcomes and Treatments After Pembrolizumab in Non–Small Cell Lung Cancer

New standards and new&#xa0;constraints redefine treatment sequencing in platinum-resistant ovarian cancer

GIST (Key Takeaways)

Clinical Editorial

Source Reference

Related by Condition/Drug

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Surgical Pembro +/- Olaparib w TMZ for rGBM

Disproportionality analysis of drug-related interstitial lung disease in patients with head and neck squamous cell carcinoma: a signal mining study

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

Durvalumab Plus Weekly Carboplatin and Paclitaxel in Cisplatin-Ineligible Recurrent or Metastati

Outcomes and Treatments After Pembrolizumab in Non–Small Cell Lung Cancer

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer

New standards and new constraints redefine treatment sequencing in platinum-resistant ovarian cancer